-+ 0.00%
-+ 0.00%
-+ 0.00%

Optimi Health plans GMP ibogaine production expansion under Health Canada license

PUBT·04/20/2026 06:04:49
Listen to the news
Optimi Health plans GMP ibogaine production expansion under Health Canada license
  • Optimi Health launched an Ibogaine initiative to extend its Health Canada-approved, GMP-licensed manufacturing platform to produce and supply ibogaine.
  • Program targets regulated ibogaine demand expected to rise as US agencies move to accelerate research, regulatory review, and patient access pathways for psychedelic drug products.
  • US Executive Order signed April 18, 2026 directed ARPA-H to match state-level psychedelic research investments, starting with USD 50 million that could be paired with Texas’ USD 50 million ibogaine commitment.
  • Optimi positioned its US market planning around an FDA Establishment Identifier received in 2025 to support future regulatory and commercial routes as they develop.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2310816_de), on April 20, 2026, and is solely responsible for the information contained therein.